Project Oncology®

There is currently a high unmet need for treating high grade glioma, but is there hope on the horizon for more treatment alternatives? Joining Dr. Jenn Simmons to break down the current standard of care and potential treatments under investigation for high grade glioma are Dr. Clark Chen, Dr. Christina Tsien, and Dr. David Piccioni.

©2019 Tocagen. All rights reserved. VV-REG-003123 10/19

Amgen's [BiTE]® technology is a targeted immuno-oncology platform designed to engage patients’ own T cells to any tumor-specific antigen to fight cancers. To learn more about the BiTE® platform’s versatility and potential for patients with difficult-to-treat cancers like multiple myeloma, acute lymphoblastic leukemia, and prostate cancer, Dr. Matt Binrholz is joined by Dr. Ajai Chari.

USA-OCF-80679

With clinical trials showing improvements over the current standard of care for HER2+ early breast cancer, incorporating new data and medications into this treatment paradigm is becoming a top priority. Listen in as Dr. Charles Geyer reviews the emerging approaches to adjuvant therapy in patients with HER2+ early breast cancer.

Early diagnosis of non-small cell lung cancer (NSCLC) can increase patients’ rate of survival, and primary care practitioners play an important role in this since they’re oftentimes on the frontlines of care. Here to discuss with Dr. John Russell how primary care practitioners like himself can expedite getting patients with NSCLC to treatment is oncologist Dr. Mark Sundermeyer.

Closing the Gaps in NSCLC is sponsored by Lilly. Content for this non-certified educational series is produced and controlled by ReachMD. This series is intended for healthcare professionals only.

There are limited treatment options in the first-line setting for patients with advanced ovarian cancer. Many patients experience disease recurrence or progression with first-line chemotherapy, with approximately 10% to 30% experiencing long-term survival.

Anti-angiogenesis agents, such as bevacizumab and nintedanib, have been investigated in clinical trials for the first-line treatment of patients with advanced ovarian cancer. Bevacizumab is now FDA approved in combination with carboplatin and paclitaxel, followed by bevacizumab as a single agent, for the treatment of women with stage III or stage IV epithelial ovarian, fallopian tube, or primary peritoneal cancer following initial surgical resection.

AXIS routinely collects and analyzes data gathered from participants in our live grand rounds programs. These questions provide incredible insight regarding the persistent challenges that clinicians face when trying to optimize treatment planning to verify where clinical practice gaps exist. This activity will provide expert answers to questions asked during a recent grand rounds series on anti-angiogenesis agents for the first-line treatment of advanced ovarian cancer.

Colonoscopies are an essential procedure, however the effectiveness in detecting colorectal cancer depends heavily on the quality of a patient’s bowel preparation. Here to discuss why some patients choose to skip this preventive procedure and what you can do to help reduce the chances of poor bowel preparation with Dr. Sophie Balzora is Dr. Carol Burke, Vice Chair of the Department of Gastroenterology, Hepatology and Nutrition at the Cleveland Clinic.

CLEN/1109/2019/USa

Joining Dr. Sophie Balzora to discuss the different bowel preparation quality assessment scales available and the advantages of each is Dr. Jonathan Cohen, Clinical Professor of Medicine at NYU School of Medicine.

CLEN/1109/2019/USb

Dr. Lawrence Hookey joins Dr. Sophie Balzora to discuss the clinical trial of a next generation low volume prep with proven efficacy and an established safety profile and tolerability data.

An inadequate bowel preparation process experience should never be the factor that keeps patients from undergoing a colonoscopy, yet that’s the case for about one in four colonoscopies. That’s why gastroenterology expert Dr. Colleen Schmitt is here to share her thoughts on CLENPIQ (sodium picosulfate, magnesium oxide and anhydrous citric acid) Oral Solution as well as three factors that may help improve the patient journey.

Lung and bronchus cancer remain the leading cause of cancer-related deaths in the United States among both men and women. The discovery of predictive biomarkers, such as sensitizing epidermal growth factor receptor (EGFR) mutations, the anaplastic lymphoma kinase (ALK) fusion oncogene, ROS1 gene rearrangements, and BRAF has led to an improvement in overall survival and progression-free survival by identifying subgroups of patients who benefit from targeted treatment; however, most NSCLC tumors lack these mutations.

NSCLC is a highly active research area and its treatment is rapidly evolving. The algorithm for the treatment of metastatic NSCLC has become increasingly complex as new therapies are being developed, including advances in the treatment of patients with metastatic NSCLC without targetable activating mutations that has progressed on prior platinum-based therapy, or chemotherapy in combination with immunotherapy, including NSCLC that has progressed rapidly on initial therapy.

Through real-world clinical cases, this activity will review available treatment options and guideline recommendations for patients with advanced NSCLC without targetable activating mutations that has progressed on initial platinum-based therapy, or immunotherapy combined with chemotherapy, and available data that can inform treatment of NSCLC that progresses rapidly on initial therapy. Discussion will include real-world patient ...